BioDelivery Sciences International, Inc.  

(Public, NASDAQ:BDSI)   Watch this stock  
Find more results for BDSI
9.26
+0.05 (0.54%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 9.06 - 9.37
52 week 7.95 - 18.48
Open 9.22
Vol / Avg. 822,955.00/1.40M
Mkt cap 484.49M
P/E     -
Div/yield     -
EPS -1.10
Shares 52.31M
Beta 2.55
Inst. own 83%
Jul 17, 2015
BioDelivery Sciences International Inc Annual Shareholders Meeting (Estimated) - 11:00AM EDT - Add to calendar
May 7, 2015
BioDelivery Sciences International Inc at Deutsche Bank Health Care Conference - 12:50PM EDT - Add to calendar
May 6, 2015
Q1 2015 BioDelivery Sciences International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 30, 2015
BioDelivery Sciences International Inc Primary Endpoint in Phase 3 Study of Clonidine Call - Webcast
Mar 16, 2015
Q4 2014 BioDelivery Sciences International Inc Earnings Call
Mar 16, 2015
Q4 2014 BioDelivery Sciences International Inc Earnings Release
Mar 9, 2015
BioDelivery Sciences International Inc at ROTH Conference - Webcast
Feb 24, 2015
BioDelivery Sciences International Inc at RBC Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -692.75% -139.22%
Operating margin -720.50% -99.48%
EBITD margin - -96.66%
Return on average assets -74.35% -85.17%
Return on average equity -130.42% -202.39%
Employees 29 -
CDP Score - -

Address

4131 Parklake Avenue, Suite 225
RALEIGH, NC 27612
United States - Map
+1-919-5829050 (Phone)
+1-919-5829051 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

BioDelivery Sciences International, Inc. (BDSI) is a specialty pharmaceutical company. BDSI is developing and commercializing, either on its own or in partnerships with third parties, applications of therapeutics to address medical needs. The Company has developed and is continuing to develop pharmaceutical products aimed principally in the areas of pain management and oncology supportive care. In formulating the Company's products and product candidates, BDSI utilizes the BioErodible MucoAdhesive (BEMA) drugs delivery technology, a small, erodible polymer film for application to the buccal mucosa. The Company's the United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its pipeline of product candidates, utilize its BEMA technology.

Officers and directors

Frank E. O'Donnell Jr. MD Executive Chairman of the Board
Age: 65
Bio & Compensation  - Reuters
Mark A. Sirgo President, Chief Executive Officer, Director
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Ernest R. De Paolantonio CPA Chief Financial Officer, Treasurer, Secretary
Age: 61
Bio & Compensation  - Reuters
Andrew L. Finn Pharm.D. Executive Vice President - Product Development
Age: 65
Bio & Compensation  - Reuters
William B. Stone Lead Independent Director
Age: 71
Bio & Compensation  - Reuters
Charles J. Bramlage Independent Director
Age: 54
Bio & Compensation  - Reuters
Thomas W. D'Alonzo Independent Director
Age: 71
Bio & Compensation  - Reuters
Barry I. Feinberg M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Samuel P. Sears Jr. Independent Director
Age: 71
Bio & Compensation  - Reuters